

AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims

Claims 1-5 (cancelled)

*Sub H* *1* *human* *polypeptide*
Claim ~~6~~ (currently amended): An isolated ~~compound~~ *polypeptide* comprising a contiguous sequence of amino acids within the sequence representing residues 149-~~197~~ *177* of the G protein of respiratory syncytial virus (RSV), wherein ~~more than one of~~ *human* ~~cysteines 173, and 176, 182 and 186~~ *polypeptide* ~~is are~~ *human* ~~absent or blocked~~, wherein said ~~compound~~ *polypeptide* is not glycosylated, and wherein said ~~compound~~ *polypeptide* has the ability to inhibit infectivity of RSV.

Claims 7-8 (cancelled)

*G contd.* *2* *the polypeptide*
Claim ~~9~~ (previously amended): A ~~compound~~ *the polypeptide* according to claim ~~6~~ *1*, wherein one or more amino acids is replaced by its corresponding D-amino acid.

Sub H *3*
Claim 10 (cancelled)

*3* *the polypeptide*
Claim ~~11~~ (previously amended): A ~~compound~~ *the polypeptide* according to claim ~~6~~ *1*, wherein the compound is labelled with a detectable marker.

*4* *the polypeptide*
Claim ~~12~~ (previously amended): A ~~compound~~ *the polypeptide* according to claim ~~11~~ *3*, wherein the detectable marker is a radioactive label.

H *5* *the polypeptide*
Claim ~~13~~ (previously amended): A ~~compound~~ *the polypeptide* according to claim ~~11~~ *3*, wherein the detectable marker is a fluorescent, chemiluminescent or enzymic marker.

Claims 14-15 (cancelled)

Claim 16 (withdrawn): An antibody directed against a compound selected from the group consisting of the compounds of Claims 1 to 10.

Claim 17 (withdrawn): An antibody according to Claim 16 which is a protective antibody.

Claim 18 (withdrawn): A composition comprising antibody selected from the group of the antibodies of Claim 16 and Claim 17.

Claims 19-20 (cancelled)

Claim 21 (withdrawn): A composition according to any one of Claim 16 in which the virus is human RSV.

G
Claim 22 (cancelled)

Claim 23 (withdrawn): A method of diagnosis of *Pneumovirus* infection, comprising exposing a biological fluid or sample from a mammal suspected of being infected with said virus to a compound selected from the group consisting of the compounds of Claims 1 to 10, and measuring the interaction between the compound and said fluid or sample.

Claim 24 (cancelled)

Claim 25 (withdrawn): A method of identification of a cell surface receptor for respiratory syncytial virus G protein, comprising the step of detection of binding of a compound selected from the group consisting of the compounds of Claims 11 to 13 to a cell surface protein.

Claim 26 (cancelled)

Claim 37 (previously added): A diagnostic composition according to claim 36, wherein one or more amino acids is replaced by its corresponding D-amino acid.

Claim 38 (cancelled)

Claim 39 (previously amended): A composition comprising ~~a compound~~ ^{the polypeptide} according to claim 6, together with a pharmaceutically acceptable carrier.

Claim 40 (cancelled)

Claim 41 (previously amended): A composition comprising ~~a compound~~ ^{the polypeptide} according to claim 6, wherein one or more amino acids is replaced by its corresponding D-amino acid.

Claim 42 (cancelled)

Claim 43 (previously added): ~~A compound~~ ^{The polypeptide} according to claim 6, comprising the amino acid sequence KQRQNKPPSKPNNDFHFEVFNFPVCSICG (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

Claim 44 (previously added): ~~A compound~~ ^{The polypeptide} according to claim 6, consisting of acetyl-KQRQNKPPSKPNNDFHFEVFNFPVCSICGamide (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

Claim 45 (previously added): A method of inhibiting the cytopathic effect of RSV, comprising contacting an RSV susceptible cell with the ~~compound~~ ^{human polypeptide} of claim 6.

Claim 46 (previously added): A method according to claim 45, wherein the contiguous sequence of amino acids represents residues 149 to 177 of the G protein of RSV. ^{human}

H
sub
H
Claim 47¹³ (previously added): A method according to claim 45, wherein the ~~compound~~^{polypeptide} comprises the amino acid sequence KQRQNKPPSKPNNDFHFEVFNFVPCSICG (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

H
Claim 48¹⁶ (previously added): A method according to claim 45, wherein the ~~compound~~^{polypeptide} is acetyl-KQRQNKPPSKPNNDFHFEVFNFVPCSICGamide (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

Claim 49 (previously added): A method of inhibiting the cytopathic effect of RSV, comprising contacting an RSV susceptible cell with a compound comprising a contiguous sequence of amino acids within the sequence representing residues 149-197 of the G protein of respiratory syncytial virus (RSV).

H
H
G
cond.
H
sub
H
Claim 50¹⁷ (currently amended): A ~~compound~~^{An isolated polypeptide} comprising a contiguous sequence of amino acids within the sequence representing residues 149-197^{human} of the G protein of respiratory syncytial virus (RSV), wherein ~~neither~~^{polypeptide} of cysteines 173, or 176, 182 and 186 is functional to form a disulfide bridge, wherein said ~~compound~~^{human} is not glycosylated, and wherein said ~~compound~~^{polypeptide} has the ability to inhibit infectivity of RSV.